- Home
- MGRX vs ALZN Comparison
MGRX vs ALZN Comparison
Compare MGRX & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- ALZN
- Stock Information
- Founded
- MGRX 2021
- ALZN 2016
- Country
- MGRX United States
- ALZN United States
- Employees
- MGRX N/A
- ALZN N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- MGRX Technology
- ALZN Health Care
- Exchange
- MGRX Nasdaq
- ALZN Nasdaq
- Market Cap
- MGRX 6.3M
- ALZN 7.0M
- IPO Year
- MGRX 2023
- ALZN 2021
- Fundamental
- Price
- MGRX $2.55
- ALZN $1.27
- Analyst Decision
- MGRX
- ALZN Strong Buy
- Analyst Count
- MGRX 0
- ALZN 1
- Target Price
- MGRX N/A
- ALZN $32.00
- AVG Volume (30 Days)
- MGRX 59.1K
- ALZN 146.8K
- Earning Date
- MGRX 11-14-2024
- ALZN 12-24-2024
- Dividend Yield
- MGRX N/A
- ALZN N/A
- EPS Growth
- MGRX N/A
- ALZN N/A
- EPS
- MGRX N/A
- ALZN N/A
- Revenue
- MGRX $755,000.00
- ALZN N/A
- Revenue This Year
- MGRX N/A
- ALZN N/A
- Revenue Next Year
- MGRX N/A
- ALZN N/A
- P/E Ratio
- MGRX N/A
- ALZN N/A
- Revenue Growth
- MGRX 52.20
- ALZN N/A
- 52 Week Low
- MGRX $2.10
- ALZN $1.06
- 52 Week High
- MGRX $16.80
- ALZN $15.06
- Technical
- Relative Strength Index (RSI)
- MGRX 53.52
- ALZN 49.66
- Support Level
- MGRX $2.44
- ALZN $1.16
- Resistance Level
- MGRX $2.62
- ALZN $1.34
- Average True Range (ATR)
- MGRX 0.12
- ALZN 0.08
- MACD
- MGRX 0.02
- ALZN 0.02
- Stochastic Oscillator
- MGRX 96.30
- ALZN 89.29
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.